NCT05209906View on ClinicalTrials.gov

An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Cancer Pain
Interventions
DRUG

Fentanyl Buccal Soluble Film

Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.

Trial Locations (1)

Unknown

MacKay Memorial Hospital, New Taipei City

All Listed Sponsors
lead

Mackay Memorial Hospital

OTHER

NCT05209906 - An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain | Biotech Hunter | Biotech Hunter